Regarding the NF-κB pathway, our finding that desrhamnosyl acteoside significantly inhibited the NF-κB signaling is in line with the understanding that NF-κB is a crucial regulator of immune and inflammatory responses in AD. This evidence concerns the gene NFKB1 and Alzheimer disease.